PMID- 34559875
OWN - NLM
STAT- MEDLINE
DCOM- 20220531
LR  - 20220630
IS  - 1543-2165 (Electronic)
IS  - 0003-9985 (Linking)
VI  - 146
IP  - 6
DP  - 2022 Jun 1
TI  - Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 
      2018 American Society of Clinical Oncology/College of American Pathologists In 
      Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 
      [HER2]/Chromosome 17 Centromere [CEP17] Ratio >/=2.0 and Average HER2 Copy Number 
      <4.0).
PG  - 701-709
LID - 10.5858/arpa.2021-0155-OA [doi]
AB  - CONTEXT.-: The American Society of Clinical Oncology/College of American 
      Pathologists updated the human epidermal growth factor receptor 2 (HER2) breast 
      carcinoma testing guideline in 2018 to address issues from uncommon HER2 
      fluorescence in situ hybridization (FISH) results. Based on the 2013 American 
      Society of Clinical Oncology/College of American Pathologists guideline, cases 
      wherein the HER2/chromosome 17 centromere (CEP17) ratio of 2.0 or more with an 
      average HER2 copy number of less than 4.0 were considered in situ hybridization 
      (ISH) positive. Under the 2018 guideline, such cases are classified as ISH Group 
      2 and are no longer considered eligible for anti-HER2 therapy when the 
      corresponding HER2 immunohistochemistry result is 0, 1+, or 2+. OBJECTIVE.-: To 
      assess the clinical, pathologic, and treatment aspects of patients with ISH Group 
      2 results. DESIGN.-: We retrospectively reviewed HER2 FISH results at our center 
      between January 2012 and December 2014 and identified and characterized cases 
      with ISH Group 2 results. RESULTS.-: Thirty-nine cases with ISH Group 2 results 
      from 39 patients were reviewed. Twenty of 39 (51%) patients received anti-HER2 
      therapy. Patients treated with HER2-targeted therapy were less likely to have 
      hormone receptor-positive tumors, compared with patients without anti-HER2 
      treatment, though not significantly (P = .30). The only significant difference 
      between the 2 patient groups was receipt of cytotoxic chemotherapy treatment (P < 
      .001). Overall, clinical outcome was similar between the 2 groups (P > .99). 
      CONCLUSIONS.-: This retrospective study with median follow-up of at least 6 years 
      shows patients with ISH Group 2 tumors had similar clinical outcomes, 
      irrespective of HER2-targeted therapy. Further analysis in the prospective 
      setting would provide valuable data that would potentially inform clinical 
      decision making.
FAU - Hoda, Raza S
AU  - Hoda RS
AD  - From the Robert J Tomsich Pathology & Laboratory Medicine Institute (Hoda, 
      McIntire, Sprague, Komforti, Downs-Kelly), Cleveland Clinic, Cleveland, Ohio.
FAU - Zarei, Shabnam
AU  - Zarei S
AD  - From the Department of Pathology, University Hospitals Cleveland Medical 
      Center/Case Western Reserve University, Cleveland, Ohio (Zarei).
FAU - McIntire, Patrick J
AU  - McIntire PJ
AD  - From the Robert J Tomsich Pathology & Laboratory Medicine Institute (Hoda, 
      McIntire, Sprague, Komforti, Downs-Kelly), Cleveland Clinic, Cleveland, Ohio.
FAU - Sprague, Cathy
AU  - Sprague C
AD  - From the Robert J Tomsich Pathology & Laboratory Medicine Institute (Hoda, 
      McIntire, Sprague, Komforti, Downs-Kelly), Cleveland Clinic, Cleveland, Ohio.
FAU - Mekhail, Yasmin
AU  - Mekhail Y
AD  - From the Department of Diagnostic Radiology (Mekhail), Cleveland Clinic, 
      Cleveland, Ohio.
FAU - Carlson, Diane L
AU  - Carlson DL
AD  - From the Department of Pathology, Cleveland Clinic Florida, Weston, Florida 
      (Carlson).
FAU - Komforti, Miglena K
AU  - Komforti MK
AD  - From the Robert J Tomsich Pathology & Laboratory Medicine Institute (Hoda, 
      McIntire, Sprague, Komforti, Downs-Kelly), Cleveland Clinic, Cleveland, Ohio.
FAU - Downs-Kelly, Erinn P
AU  - Downs-Kelly EP
AD  - From the Robert J Tomsich Pathology & Laboratory Medicine Institute (Hoda, 
      McIntire, Sprague, Komforti, Downs-Kelly), Cleveland Clinic, Cleveland, Ohio.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arch Pathol Lab Med
JT  - Archives of pathology & laboratory medicine
JID - 7607091
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/metabolism
MH  - *Breast Neoplasms/pathology
MH  - Centromere/genetics
MH  - Chromosomes, Human, Pair 17/genetics
MH  - *DNA Copy Number Variations
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Medical Oncology
MH  - Pathologists
MH  - Prospective Studies
MH  - Receptor, ErbB-2/genetics/metabolism
MH  - Retrospective Studies
EDAT- 2021/09/25 06:00
MHDA- 2022/06/01 06:00
CRDT- 2021/09/24 17:21
PHST- 2021/05/26 00:00 [accepted]
PHST- 2021/09/25 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2021/09/24 17:21 [entrez]
AID - 470823 [pii]
AID - 10.5858/arpa.2021-0155-OA [doi]
PST - ppublish
SO  - Arch Pathol Lab Med. 2022 Jun 1;146(6):701-709. doi: 10.5858/arpa.2021-0155-OA.